CEOs of two U.S. health systems testified June 4 before a House subcommittee on the oversight of the 340B drug pricing program, advocating for the preservation of the protections that have been in place for hospitals and patients since 1992.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
